NO934355L - Proteinformulering omfattende veksthormon - Google Patents

Proteinformulering omfattende veksthormon

Info

Publication number
NO934355L
NO934355L NO934355A NO934355A NO934355L NO 934355 L NO934355 L NO 934355L NO 934355 A NO934355 A NO 934355A NO 934355 A NO934355 A NO 934355A NO 934355 L NO934355 L NO 934355L
Authority
NO
Norway
Prior art keywords
growth hormone
pct
formulation
citrate
buffer substance
Prior art date
Application number
NO934355A
Other languages
English (en)
Other versions
NO310804B1 (no
NO934355D0 (no
Inventor
Staffan Castensson
Ebba Florin-Robertsson
Elvy Hoekby
Sirkka Thome
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20385860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO934355(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO934355D0 publication Critical patent/NO934355D0/no
Publication of NO934355L publication Critical patent/NO934355L/no
Publication of NO310804B1 publication Critical patent/NO310804B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO19934355A 1992-04-03 1993-11-30 Stabilisert injiserbar formulering av humant veksthormon og fremgangsmåte for fremstilling derav NO310804B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation
PCT/SE1993/000281 WO1993019776A1 (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone

Publications (3)

Publication Number Publication Date
NO934355D0 NO934355D0 (no) 1993-11-30
NO934355L true NO934355L (no) 1993-12-01
NO310804B1 NO310804B1 (no) 2001-09-03

Family

ID=20385860

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19934355A NO310804B1 (no) 1992-04-03 1993-11-30 Stabilisert injiserbar formulering av humant veksthormon og fremgangsmåte for fremstilling derav

Country Status (15)

Country Link
US (1) US5567677A (no)
EP (1) EP0587858B2 (no)
JP (1) JP3268557B2 (no)
AT (1) ATE196092T1 (no)
AU (1) AU666007B2 (no)
CA (1) CA2102693C (no)
DE (1) DE69329367T3 (no)
DK (1) DK0587858T3 (no)
ES (1) ES2150940T5 (no)
GR (1) GR3034925T3 (no)
NO (1) NO310804B1 (no)
NZ (1) NZ251498A (no)
PT (1) PT587858E (no)
SE (1) SE9201073D0 (no)
WO (1) WO1993019776A1 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711731B (en) 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
CA2378949C (en) * 1999-07-12 2015-03-31 Grandis Biotech Gmbh Growth hormone formulations
EP1309312A2 (en) 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
WO2002092619A2 (en) * 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
AU2003217783A1 (en) * 2002-02-27 2003-09-09 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20070065469A1 (en) * 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
MXPA05000413A (es) * 2002-07-09 2005-07-22 Sandoz Ag Formulaciones liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden 1,2-propilenglicol.
US20060252682A1 (en) * 2003-03-18 2006-11-09 Ares Trading S.A. Liquid growth hormone formulation and process of preparation thereof
WO2005063298A1 (en) 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
AP2007003869A0 (en) * 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
NZ552842A (en) * 2004-08-03 2010-05-28 Univ Columbia Rage fusion proteins and methods of use
CN101022822B (zh) * 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
EA011673B1 (ru) * 2004-11-09 2009-04-28 Арес Трейдинг С.А. Способ очистки fsh
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
BRPI0520498B8 (pt) 2005-08-26 2021-05-25 Ares Trading Sa processo para fabricação de interferon beta humano recombinante glicosilado, e uso de um meio de cultura isento de soro
EP1948221B1 (en) * 2005-11-02 2015-04-08 Syneron Medical Ltd. Human growth hormone patch formulations
US8604175B2 (en) * 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
RU2431804C2 (ru) * 2005-12-23 2011-10-20 ДжиКоудер Системз АБ Шаблон позиционирования
NZ569545A (en) * 2006-02-09 2011-11-25 Transtech Pharma Inc Rage fusion proteins and methods of use for treating inflammation
MX2008013863A (es) * 2006-05-05 2008-11-14 Transtech Pharma Inc Proteinas de fusion de rage y sus metodos de uso.
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20100249381A1 (en) * 2007-10-22 2010-09-30 David Delvaille Method for Purifying FC-Fusion Proteins
JP2011500757A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製方法
CN102803292A (zh) 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法
US20120108512A1 (en) * 2009-05-07 2012-05-03 Novo Nordisk Health Care Ag Stable pharmaceutical compositions of peptide derivatized using an oxime linker
ES2532007T3 (es) * 2009-11-17 2015-03-23 Ipsen Pharma S.A.S. Formulación para combinación de HGH y rhIGF-1
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CA2925416A1 (en) * 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
WO2016011281A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries Ltd. FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
DE3579911D1 (de) * 1984-12-24 1990-10-31 Sumitomo Pharma Stabiles grf-praeparat.
AU6073386A (en) * 1985-07-30 1987-02-05 International Minerals & Chemical Corporation Stabilization of growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
ATE82506T1 (de) * 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
US4837202A (en) † 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH01308235A (ja) * 1988-06-03 1989-12-12 Yamanouchi Pharmaceut Co Ltd ヒト成長ホルモン経鼻剤
US5008244A (en) * 1989-05-15 1991-04-16 Pitman-Moore, Inc. Method for increasing fertility in animals
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
IN172427B (no) * 1989-11-14 1993-07-24 Fidia Spa
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
CA2133205C (en) * 1992-04-30 2007-04-17 Robert L. Swift Stable polypeptide composition
MD1699F2 (ro) * 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei

Also Published As

Publication number Publication date
DE69329367D1 (de) 2000-10-12
EP0587858A1 (en) 1994-03-23
NO310804B1 (no) 2001-09-03
US5567677A (en) 1996-10-22
NO934355D0 (no) 1993-11-30
AU3913593A (en) 1993-11-08
ES2150940T3 (es) 2000-12-16
WO1993019776A1 (en) 1993-10-14
CA2102693C (en) 2008-06-17
JP3268557B2 (ja) 2002-03-25
JPH06508156A (ja) 1994-09-14
SE9201073D0 (sv) 1992-04-03
DK0587858T3 (da) 2000-12-18
ES2150940T5 (es) 2008-04-16
EP0587858B1 (en) 2000-09-06
AU666007B2 (en) 1996-01-25
NZ251498A (en) 1995-07-26
PT587858E (pt) 2001-02-28
CA2102693A1 (en) 1993-10-04
DE69329367T3 (de) 2008-06-19
EP0587858B2 (en) 2007-11-14
DE69329367T2 (de) 2001-06-21
ATE196092T1 (de) 2000-09-15
GR3034925T3 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
SE9201073D0 (sv) Protein formulation
EP0747092A3 (en) Dissolution liquid for drug in iontophoresis
CA2275890A1 (en) Stable liquid interferon formulations
DE59504750D1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
DK0910399T3 (da) Stabilt farmaceutisk BDNF-præparat
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
ATE115147T1 (de) Rekombinantes alveolares oberflächenaktives protein.
DK1017413T4 (da) Flydende formulering af interferon-beta
ES2187820T3 (es) Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.
DE69805983D1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
Li Recent studies on the problems involved in the preparation, properties and bioassay of adrenocorticotrophic hormone
Holbrook et al. The identification of a peptide in human parotid saliva particularly active in enhancing the glycolytic activity of the salivary micro-organisms.
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DK0641216T3 (da) Farmaceutisk præparat indeholdende IL-6
KR860006982A (ko) 안정한 감마 인터페론 제형의 제조방법
Donohue Jr et al. Glucose-6-phosphate dehydrogenase Partial characterization of the rat liver and uterine enzymes
Leaver Studies on certain peptide fractions isolated from human dentine
SE9302006D0 (sv) Protein formulation
Lafeber Comparison of PTH and hypocalcin in mammalian and teleost bioassays
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio